Trial · NCT03319940
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with dose limiting toxicities (DLT) for all indications | 6 months | |
| Primary | Number of participants with treatment-emergent adverse events (AEs) for all indications | 4 years | |
| Primary | Number of participants with treatment-related AEs for all indications | 4 years | |
| Primary | Number of participants with clinically significant changes in vital signs for all indications | 4 years | |
| Primary | Number of participants with significant changes in electrocardiogram (ECG) for all indications | 4 years | |
| Primary | Number of participants with significant changes in physical examinations for all indications | 4 years | |
| Primary | Number of participants with significant changes in clinical laboratory tests for all indications | 4 years | |
| Secondary | Maximum observed concentration (Cmax) following intravenous administration for all indications | 4 years | |
| Secondary | Minimum observed concentration (Cmin) following intravenous administration for all indications | 4 years | |
| Secondary | Area under the concentration-time curve (AUC) over the 2 week dosing interval for all indications | 4 years | |
| Secondary | Accumulation following multiple dosing for all indications | 4 years | |
| Secondary | Half-life (t1/2) following intravenous administration for all indications | 4 years | |
| Secondary | Objective Response (OR) per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 | 4 years | Only for parts A, D, E, F, and G |
| Secondary | Duration of Response (DOR) for all indications | 4 years | |
| Secondary | Time to Response (TTR) | 4 years | |
| Secondary | 9-month Progression-Free Survival (PFS) for all indications | 9 months | |
| Secondary | 9-month Overall Survival (OS) for all indications | 9 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03319940/registered